Új lipidcsökkento a láthatáron, a rosuvastatin

Translated title of the contribution: A new lipid lowering drug in the horizont, the rosuvastatin

László Márk, G. Paragh

Research output: Contribution to journalArticle

Abstract

According to the Third Joint Task Force European guidelines and Hungarian national recommendations administration of platelet aggregation inhibitors, beta-blockers, ACE-inhibitors and statins is essential in patients with known cardiovascular disease for the prevention of new events. Statins became the drugs of first choice for the prevention because of their favourable effects in the reduction of cardiovascular and total mortality, and in the regression or slowing the progression of atherosclerotic process. A new agent in the class of statins, rosuvastatin is a synthetic compound, selectively taken up by hepatic cells, and due to its methylsulfonamid group inhibits to a greater extend the hydroxy-methyl-glutaryl-coenzyme-A reductase enzyme. Administration of daily 10-40 mg rosuvastatin has been shown to reduce the LDL-cholesterol level by 52-63%, and increase the HDL-cholesterol level up to 14%. These effects are greater than that of other currently available statins. Rosuvastatin has beneficial effects not only in hypercholesterolaemia, but in mixed hyperlipidaemia, hypertriglyceridaemia and lipid abnormalities in diabetes mellitus as well. This compound is well tolerated, has a good safety profile, due to its pharmacological properties can be applied in combination with other lipid lowering drugs. Its effects in monotherapy and the combination possibilities offer the physicians a new drug, which could help to achieve target lipid levels to a greater extend.

Original languageHungarian
Pages (from-to)1869-1876
Number of pages8
JournalOrvosi Hetilap
Volume146
Issue number36
Publication statusPublished - 2005

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Pharmaceutical Preparations
Hypertriglyceridemia
Platelet Aggregation Inhibitors
Advisory Committees
Hypercholesterolemia
Hyperlipidemias
Angiotensin-Converting Enzyme Inhibitors
LDL Cholesterol
HDL Cholesterol
Hepatocytes
Diabetes Mellitus
Oxidoreductases
Cardiovascular Diseases
Joints
Pharmacology
Guidelines
Physicians
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Új lipidcsökkento a láthatáron, a rosuvastatin. / Márk, László; Paragh, G.

In: Orvosi Hetilap, Vol. 146, No. 36, 2005, p. 1869-1876.

Research output: Contribution to journalArticle

Márk, L & Paragh, G 2005, 'Új lipidcsökkento a láthatáron, a rosuvastatin', Orvosi Hetilap, vol. 146, no. 36, pp. 1869-1876.
Márk, László ; Paragh, G. / Új lipidcsökkento a láthatáron, a rosuvastatin. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 36. pp. 1869-1876.
@article{db38212594fb406d9a53666b49b4032e,
title = "{\'U}j lipidcs{\"o}kkento a l{\'a}that{\'a}ron, a rosuvastatin",
abstract = "According to the Third Joint Task Force European guidelines and Hungarian national recommendations administration of platelet aggregation inhibitors, beta-blockers, ACE-inhibitors and statins is essential in patients with known cardiovascular disease for the prevention of new events. Statins became the drugs of first choice for the prevention because of their favourable effects in the reduction of cardiovascular and total mortality, and in the regression or slowing the progression of atherosclerotic process. A new agent in the class of statins, rosuvastatin is a synthetic compound, selectively taken up by hepatic cells, and due to its methylsulfonamid group inhibits to a greater extend the hydroxy-methyl-glutaryl-coenzyme-A reductase enzyme. Administration of daily 10-40 mg rosuvastatin has been shown to reduce the LDL-cholesterol level by 52-63{\%}, and increase the HDL-cholesterol level up to 14{\%}. These effects are greater than that of other currently available statins. Rosuvastatin has beneficial effects not only in hypercholesterolaemia, but in mixed hyperlipidaemia, hypertriglyceridaemia and lipid abnormalities in diabetes mellitus as well. This compound is well tolerated, has a good safety profile, due to its pharmacological properties can be applied in combination with other lipid lowering drugs. Its effects in monotherapy and the combination possibilities offer the physicians a new drug, which could help to achieve target lipid levels to a greater extend.",
keywords = "Cholesterol, LDL-cholesterol target levels, Lipids, Statins",
author = "L{\'a}szl{\'o} M{\'a}rk and G. Paragh",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1869--1876",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "36",

}

TY - JOUR

T1 - Új lipidcsökkento a láthatáron, a rosuvastatin

AU - Márk, László

AU - Paragh, G.

PY - 2005

Y1 - 2005

N2 - According to the Third Joint Task Force European guidelines and Hungarian national recommendations administration of platelet aggregation inhibitors, beta-blockers, ACE-inhibitors and statins is essential in patients with known cardiovascular disease for the prevention of new events. Statins became the drugs of first choice for the prevention because of their favourable effects in the reduction of cardiovascular and total mortality, and in the regression or slowing the progression of atherosclerotic process. A new agent in the class of statins, rosuvastatin is a synthetic compound, selectively taken up by hepatic cells, and due to its methylsulfonamid group inhibits to a greater extend the hydroxy-methyl-glutaryl-coenzyme-A reductase enzyme. Administration of daily 10-40 mg rosuvastatin has been shown to reduce the LDL-cholesterol level by 52-63%, and increase the HDL-cholesterol level up to 14%. These effects are greater than that of other currently available statins. Rosuvastatin has beneficial effects not only in hypercholesterolaemia, but in mixed hyperlipidaemia, hypertriglyceridaemia and lipid abnormalities in diabetes mellitus as well. This compound is well tolerated, has a good safety profile, due to its pharmacological properties can be applied in combination with other lipid lowering drugs. Its effects in monotherapy and the combination possibilities offer the physicians a new drug, which could help to achieve target lipid levels to a greater extend.

AB - According to the Third Joint Task Force European guidelines and Hungarian national recommendations administration of platelet aggregation inhibitors, beta-blockers, ACE-inhibitors and statins is essential in patients with known cardiovascular disease for the prevention of new events. Statins became the drugs of first choice for the prevention because of their favourable effects in the reduction of cardiovascular and total mortality, and in the regression or slowing the progression of atherosclerotic process. A new agent in the class of statins, rosuvastatin is a synthetic compound, selectively taken up by hepatic cells, and due to its methylsulfonamid group inhibits to a greater extend the hydroxy-methyl-glutaryl-coenzyme-A reductase enzyme. Administration of daily 10-40 mg rosuvastatin has been shown to reduce the LDL-cholesterol level by 52-63%, and increase the HDL-cholesterol level up to 14%. These effects are greater than that of other currently available statins. Rosuvastatin has beneficial effects not only in hypercholesterolaemia, but in mixed hyperlipidaemia, hypertriglyceridaemia and lipid abnormalities in diabetes mellitus as well. This compound is well tolerated, has a good safety profile, due to its pharmacological properties can be applied in combination with other lipid lowering drugs. Its effects in monotherapy and the combination possibilities offer the physicians a new drug, which could help to achieve target lipid levels to a greater extend.

KW - Cholesterol

KW - LDL-cholesterol target levels

KW - Lipids

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=33846424626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846424626&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 1869

EP - 1876

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 36

ER -